570 Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an {IV} infusion every 3 weeks to patients with advanced solid tumors

R.J. Fram; L.E. Garbo; G.J. Weiss; D. Shkolny; A.V. Yurkovetskiy; C. Bethune; R.K. Ramanathan; M.J. Edelman; E.A. Sausville

首页> 外文期刊>European Journal of Cancer Supplements >570 Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an {IV} infusion every 3 weeks to patients with advanced solid tumors

【24h】

570 Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an {IV} infusion every 3 weeks to patients with advanced solid tumors

机译：570一种新型水溶性喜树碱偶联物XMT-1001的第1阶段研究，每3周输注一次{{IV }，用于晚期实体瘤患者

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2010年第7期|共页
作者
R.J. Fram; L.E. Garbo; G.J. Weiss; D. Shkolny; A.V. Yurkovetskiy; C. Bethune; R.K. Ramanathan; M.J. Edelman; E.A. Sausville;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 570 Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an {IV} infusion every 3 weeks to patients with advanced solid tumors [J] . R.J. Fram, L.E. Garbo, G.J. Weiss, European Journal of Cancer Supplements . 2010,第7期

机译：570一种新型水溶性喜树碱偶联物XMT-1001的第1阶段研究，每3周输注一次{{IV }，用于晚期实体瘤患者
2. A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors. [J] . Mross K, Richly H, Schleucher N, Annals of oncology: official journal of the European Society for Medical Oncology . 2004,第8期

机译：喜树碱糖缀合物BAY 38-3441的I期临床和药代动力学研究，用于晚期实体瘤患者的每日输注。
3. Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies [J] . Eric X. Chen, Gerald Batist, Lillian L. Siu, Investigational New Drugs . 2005,第5期

机译：Bay 38-3441（喜树碱糖缀合物）的第一阶段和药代动力学研究，在晚期实体恶性肿瘤患者中，每3周每天输注30分钟，每5天一次，持续30分钟
4. Design of fluorescence dye-conjugated peptides for the receptor-targeted optical imaging of tumors using solid-phase peptide libraries [C] . Kai Licha, Freie Univ. Berlin, Berlin, Molecular Imaging: Reporters, Dyes, Markers, and Instrumentation . 2000

机译：使用固相肽库设计荧光染料偶联肽，用于肿瘤的受体靶向光学成像
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. An open-label dose-escalation safety and pharmacokinetics phase I study of ombrabulin a vascular disrupting agent administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors [O] . H. Murakami, T. Kurata, Y. Onozawa, -1

机译：一项开放性剂量递增安全性和药代动力学I期研究ombrabulin（一种血管破裂剂）每3周对日本晚期实体瘤患者进行30分钟静脉输注
7. An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors [O] . H. Murakami, T. Kurata, Y. Onozawa, 2014

机译：一项开放性，剂量递增，安全性和药代动力学I期研究ombrabulin（一种血管破裂剂），在日本患有晚期实体瘤的患者中每3周静脉输注30分钟

570 Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an {IV} infusion every 3 weeks to patients with advanced solid tumors

著录项

相似文献

相关主题

期刊订阅